Organon (OGN) and Samsung Bioepis said Tuesday that the US Food and Drug Administration has designated Hadlima high and low concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to AbbVie's (ABBV) Humira.

The FDA previously granted interchangeability designation to Hadlima low-concentration prefilled syringe and single-dose vial in June 2024, the company said.

An interchangeability designation enables a pharmacist to substitute the reference product with a biosimilar without the need to consult the prescriber, the company said.

Shares of Organon were 5% higher in recent trading.

Price: 9.11, Change: +0.42, Percent Change: +4.78